
EQT sells WS Audiology to new fund
EQT has sold WS Audiology, a Danish manufacturer of hearing aids, from its EQT VI fund to a consortium including EQT VIII and Swiss-based investor Santo Holdings.
Following the closing of the transaction, EQT VII, EQT VIII, Santo Holdings, the Tøpholm and Westermann families, and a group of minority co-investors will own WS Audiology.
EQT says that WS Audiology is the largest producer of hearing aids based on volume. It sells 5.5 million units a year and has revenues of EUR 2bn.
Filed accounts show that it had revenues of EUR 1.7bn in the year to September 2020, with EBITDA of EUR 201m and adjusted EBITDA of 331m.
Revenue growth was 4% in its 2019/20 financial year and EQT says that the company's EBITDA has grown more than 20% since it first invested in 2014.
The adjustment comes from significant one-time costs related to the 2019 merger between Sivantos (acquired by EQT VI in 2014) and Widex, owned by the Tøpholm and Westermann families, according to the accounts.
At the time, the joint entity was valued at €7bn, according to the GP.
EQT closed EQT VIII in February 2018 on EUR 10.75bn, according to Unquote Data – it is already 80% deployed.
WS Audiology said it aimed to expand with increased market penetration and investment in R&D and its supply chain. Its sales were hit in early 2020 by a shortage of lithium-ion components, the company said.
Company
Formed in 2019 through the merger of Sivantos and Widex, WS Audiology manufactures hearing aids and auditory testing devices under a suite of 14 brands. It claims to be active in 125 countries globally and has headquarters in Lynge, Denmark, and Singapore.
People
EQT – Marcus Brennecke, Kasper Grundtvig Knokgaard (partners).
Latest News
CVC acquires Scan Global logistics from AEA Investors
AEA and management have reinvested for a minority stake in the Danish logistics provider
Eurazeo shakes up executive board; CEO Virginie Morgon to depart
New board members are chairmen Christophe Bavière and William Kadouch-Chassaing, as well as Sophie Flak and Olivier Millet
Seventure preps third generation of microbiome fund
Health for Life III to be slightly larger than EUR 250m predecessor; will invest in Europe, US, Israel
Idacapital targets close to USD 30m for impact fund
Turkish VC seeks to raise USD 5m every six months for new rolling investment vehicle